Physician profile
Cesar Yu
NPI 1225135825
$5,147.08
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2020: $837 · 2021: $813 · 2022: $1,091 · 2023: $1,159 · 2024: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,492 · Entertainment: $32.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,491.58 |
| Entertainment | $32.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,418.15 | 2019-2024 | Breztri, Farxiga, Fasenra |
| Janssen Pharmaceuticals, INC | $698.41 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $417.36 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $356.08 | 2020-2023 | Jardiance |
| Amgen INC. | $309.48 | 2019-2021 | |
| Novo Nordisk INC | $223.64 | 2019-2023 | Wegovy |
| Novartis Pharmaceuticals Corporation | $175.82 | 2019-2022 | |
| Mylan Specialty L.P. | $142.49 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $94.69 | 2020-2023 | Eliquis |
| Sunovion Pharmaceuticals INC. | $76.16 | 2019 | |
| Pfizer INC. | $47.51 | 2019-2024 | |
| Glaxosmithkline, LLC. | $36.84 | 2022-2023 | Bexsero, Shingrix |
| Optos, INC. | $32.68 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Astellas Pharma US INC | $30.59 | 2021 | |
| Daiichi Sankyo INC. | $28.79 | 2020-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, Ltd. | $19.30 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $13.72 | 2019 | |
| Masimo Corporation | $13.44 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.